Strategies for antigen loading of dendritic cells to enhance the antitumor immune response - PubMed (original) (raw)
. 2002 Mar 15;62(6):1884-9.
Stephen Voss, Ryan Wilcox, Tamekia L Wakefield, Koji Tamada, Dallas Flies, Andrei Chapoval, Jun Lu, Jan L Kasperbauer, Douglas Padley, Richard Vile, Dennis Gastineau, Peter Wettstein, Lieping Chen
Affiliations
- PMID: 11912169
Strategies for antigen loading of dendritic cells to enhance the antitumor immune response
Scott E Strome et al. Cancer Res. 2002.
Abstract
Dendritic cells (DCs) primed with tumor antigens can effectively mediate the regression of a variety of established solid malignancies in both murine and human models. Despite such clinical efficacy, the optimal means of DC priming is unknown. The goal of this study was to compare three methods of tumor preparation: irradiation, boiling, or freeze thaw lysis for DC priming. Mouse bone marrow-derived DCs were loaded with defined ratios of E.G7 tumor cells expressing a model tumor antigen, OVA. Sensitized DCs were used for stimulation of OVA-specific CTLs derived from OT-1 T-cell receptor transgenic mice. IFN-gamma release, determined by ELISA at 24 and 48 h, was used to assess the expression of antigens by DCs. DCs loaded with irradiated tumors were effective stimulators for OT-1 CTLs, whereas DCs stimulated with freeze-thawed or boiled tumors did not stimulate IFN-gamma production. Freeze-thaw lysis appeared to inhibit CTL activity in vitro and in two of three cases, this effect was not overcome by the addition of OVA. The ability to load irradiated tumor cells was reproduced in two analogous human melanoma models using melanoma cell lines expressing gp100 and CTL clones specific for a gp100 melanoma antigen. Consistent with the in vitro data, only DC/irradiated tumor vaccines were effective in preventing or delaying outgrowth of E.G7 and a poorly immunogenic murine squamous cell carcinoma (SCCVII), on local tumor challenge. These data demonstrate that the method of tumor cell preparation clearly influences the ability of DCs to present antigen to T cells. Correlation of in vitro data with the generation of protective immunity in vivo suggests the utility of irradiated tumor-primed DCs as a means to generate protective immunity in patients with solid malignancies.
Similar articles
- Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J, Saffold S, Cao X, Krauss J, Chen W. Wang J, et al. J Immunol. 1998 Nov 15;161(10):5516-24. J Immunol. 1998. PMID: 9820528 - Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines.
Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Garcia-Prats MD, DeLeo AB, Lotze MT. Mayordomo JI, et al. Stem Cells. 1997;15(2):94-103. doi: 10.1002/stem.150094. Stem Cells. 1997. PMID: 9090785 Review. - The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer.
Matera L. Matera L. Cancer Treat Rev. 2010 Apr;36(2):131-41. doi: 10.1016/j.ctrv.2009.11.002. Epub 2009 Dec 1. Cancer Treat Rev. 2010. PMID: 19954892 Review.
Cited by
- Therapeutic cell-based vaccines for glioblastoma multiforme.
Pour ME, Moghadam SG, Shirkhani P, Sahebkar A, Mosaffa F. Pour ME, et al. Med Oncol. 2023 Nov 12;40(12):354. doi: 10.1007/s12032-023-02220-5. Med Oncol. 2023. PMID: 37952224 Review. - Intracellular Salmonella delivery of an exogenous immunization antigen refocuses CD8 T cells against cancer cells, eliminates pancreatic tumors and forms antitumor immunity.
Raman V, Howell LM, Bloom SMK, Hall CL, Wetherby VE, Minter LM, Kulkarni AA, Forbes NS. Raman V, et al. Front Immunol. 2023 Oct 5;14:1228532. doi: 10.3389/fimmu.2023.1228532. eCollection 2023. Front Immunol. 2023. PMID: 37868996 Free PMC article. - Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing.
Li W, Zhang B, Cao W, Zhang W, Li T, Liu L, Xu L, Gao F, Wang Y, Wang F, Xing H, Jiang Z, Shi J, Bian Z, Song Y. Li W, et al. Exp Hematol Oncol. 2023 May 8;12(1):44. doi: 10.1186/s40164-023-00402-5. Exp Hematol Oncol. 2023. PMID: 37158921 Free PMC article. - Gene delivery in adherent and suspension cells using the combined physical methods.
Kardani K, Milani A, Bolhassani A. Kardani K, et al. Cytotechnology. 2022 Apr;74(2):245-257. doi: 10.1007/s10616-022-00524-4. Epub 2022 Feb 3. Cytotechnology. 2022. PMID: 35464169 Free PMC article. - The generation and application of antigen-specific T cell therapies for cancer and viral-associated disease.
Hont AB, Powell AB, Sohai DK, Valdez IK, Stanojevic M, Geiger AE, Chaudhary K, Dowlati E, Bollard CM, Cruz CRY. Hont AB, et al. Mol Ther. 2022 Jun 1;30(6):2130-2152. doi: 10.1016/j.ymthe.2022.02.002. Epub 2022 Feb 9. Mol Ther. 2022. PMID: 35149193 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources